Setra

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Setra

What is Setra?

Setra is a medication belonging to the class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It is primarily used to manage various mental health conditions by affecting the chemical balance in the brain.

Therapeutic Use

Setra is commonly prescribed for the treatment of several psychological and emotional conditions, including:

  • Major Depressive Disorder: Helping to alleviate persistent feelings of sadness and loss of interest.
  • Panic Disorder: Assisting in the management of sudden episodes of intense fear or panic attacks.
  • Obsessive-Compulsive Disorder (OCD): Addressing repetitive thoughts and behaviors.
  • Social Anxiety Disorder: Reducing excessive self-consciousness and fear in social situations.
  • Post-Traumatic Stress Disorder (PTSD): Helping individuals process and manage symptoms following a traumatic event.

Mechanism of Action

The active component in Setra works by increasing the levels of serotonin, a neurotransmitter, in the brain. Serotonin is often referred to as a chemical messenger that helps regulate mood, sleep, and appetite. By preventing the reabsorption (reuptake) of serotonin by nerve cells, the medication allows more of this messenger to be available to transmit signals between neurons, which can lead to improved emotional balance and a reduction in anxiety-related symptoms.

Form and Appearance

Setra is typically available in tablet form for oral administration. It is designed to be integrated into a long-term treatment plan, as the stabilization of neurotransmitter levels usually occurs gradually over several weeks.

Regulatory References

  1. NICE Guideline on Sertraline/Depression

What side effects are possible with Setra?

Possible Side Effects and Safety Information

The safety profile of Setra (Sertraline) is formally defined by regulatory agencies, classifying potential adverse reactions by frequency and affected physiological system. As a Selective Serotonin Reuptake Inhibitor (SSRI), its profile includes effects on the gastrointestinal and nervous systems, as documented in official prescribing information.


Official Adverse Reactions by Frequency

Adverse reactions are classified according to incidence observed in clinical trials:

  • Very Common (Occurs in 10%): Nausea, Diarrhea or Loose Stool, Insomnia, Dizziness, and Ejaculation Failure (specifically noted in males).
  • Common (Occurs in 1% to <10%): Dry mouth, Vomiting, Decreased Appetite, Somnolence (Drowsiness), Tremor, Headache, Fatigue, Increased Sweating (Hyperhidrosis), Decreased Libido, and Female Anorgasmia.

Serious Safety Considerations

Regulatory documents emphasize specific, clinically significant safety concerns. There is a documented risk of Serotonin Syndrome, a potentially serious condition involving mental status changes and neuromuscular abnormalities, particularly when co-administered with other serotonergic agents. The official labeling also notes an increased risk of Abnormal Bleeding and the potential for Activation of Mania or Hypomania, requiring screening for bipolar disorder history.

Population-Specific Notes

Specific safety considerations exist for certain populations. In children and adolescents, there is an increased risk of suicide-related behaviors and hostility. Older adults may be at a greater risk for developing Hyponatremia (low sodium levels). Furthermore, hepatic impairment necessitates caution, and use in moderate to severe liver disease is generally not recommended due to reduced drug clearance.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations: Overdosage typically results in central nervous system effects, including somnolence, agitation, tremor, dizziness, and altered mental status. Gastrointestinal disturbances such as nausea and vomiting are also commonly documented. Cardiovascular effects such as tachycardia (rapid heartbeat) may occur.

Physiological systems affected (as stated in label): The primary systems affected are the CNS and gastrointestinal tract. However, the regulatory documents cite the risk of significant cardiovascular toxicity, including QTc interval prolongation, which necessitates careful monitoring.

Dose-related or exposure-related factors (if applicable): Fatal outcomes have been reported, primarily when Sertraline was ingested in combination with other drugs and/or alcohol. Overdose of Sertraline alone is generally associated with a wider margin of safety.

Population-specific overdose notes (if applicable): Caution is advised for patients with existing hepatic impairment due to reduced clearance. Additionally, elderly patients may be at greater risk of developing hyponatraemia, a condition which can lead to severe complications like seizures or coma.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The potential for severe, life-threatening complications, including Serotonin Syndrome, seizures, and coma, is officially documented, requiring aggressive medical treatment.

Regulatory basis (EMA / FDA / etc.): The management protocol is based on regulatory guidance that details required monitoring and procedural constraints.

Overdose-context constraints (as defined in official documents): There are no specific antidotes known for Sertraline overdose. Procedural interventions like forced diuresis or dialysis are officially stated as unlikely to be beneficial.


Resulting Overdose Structure

Official overdose statements:

  • Symptoms include somnolence, agitation, tremor, and tachycardia.
  • Serious outcomes include Serotonin Syndrome and the risk of QTc prolongation.
  • Immediate medical attention is required for any suspected overdose.
  • Management requires general symptomatic and supportive measures, along with continuous cardiac (ECG) and vital sign monitoring.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by its potential for severe CNS and systemic effects, which requires immediate medical intervention. The required management focuses on supportive care and intensive cardiac monitoring, as the official documentation confirms that no specific antidote is available.

Therapeutic Uses of Setra

What Setra Treats: Main Uses and Benefits

Setra (Sertraline) is commonly used to help with symptomatic support across multiple clinical contexts, including conditions characterized by periods of heightened symptoms such as Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).

The medication is applied across domains where additional symptomatic support is needed. It is relevant for easing symptoms associated with multiple conditions: MDD, OCD, Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD).

Therapeutic Focus and Relief

The medication helps address symptom clusters that may become intense or disruptive, such as symptoms related to systemic imbalance (low mood) and heightened physiological activity (extreme fear). Setra is generally applied in clinical settings that involve acute or unstable symptom patterns, and is relevant for easing symptoms that interfere with daily functioning.

This supportive relief is considered relevant for managing severe manifestations in adults and in pediatric patients. It assists with maintaining functional stability and contributes to easing the overall symptom load.


Quick Fact: Relief for Symptoms of Discomfort and Tension

Setra is commonly used to help with the symptomatic management of Panic Disorder and Social Anxiety Disorder, supporting patients during episodes of heightened discomfort and contributing to easing symptoms of increased neurological or muscular activity.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Setra?

Setra (Sertraline) eligibility is determined by official regulatory classifications that specify who is approved to use the medicine and who is formally prohibited.

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to sertraline, or by patients who are concurrently taking Monoamine Oxidase Inhibitors (MAOIs) or the drug Pimozide.

Eligibility across age groups is limited. Use is approved for adults for all labeled indications. In pediatric patients (aged 6 to 17 years), use is approved only for Obsessive-Compulsive Disorder (OCD); use in children under 6 years is officially not recommended.

Patients with specific health conditions require restricted or conditional use. Those with mild hepatic impairment must use Setra with caution, often requiring a lower dose. Use is not recommended for patients with moderate to severe hepatic impairment due to insufficient data, though no adjustment is required for renal impairment. Caution is also advised for patients with a history of mania, hypomania, or seizure disorders.

Setra is generally not recommended for use during pregnancy or lactation unless the anticipated clinical benefit for the mother is deemed to outweigh the potential risk to the child, a status defined in official regulatory labeling.

What should I know about interactions with other medicines?

The official regulatory documents establish specific constraints regarding the use of Setra with other medicines due to both pharmacodynamic and pharmacokinetic effects.

Contraindicated Combinations

Setra is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and methylene blue. A 14-day washout period is required after stopping either an MAOI before starting Setra, or vice versa, to avoid the risk of serious adverse reactions. Use with Pimozide and Thioridazine is also contraindicated. Additionally, the Setra oral solution formulation is contraindicated for use with Disulfiram.

Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with other serotonergic agents (e.g., SSRIs, triptans, opioids) may increase the risk of Serotonin Syndrome and requires caution. Concomitant use with drugs that affect hemostasis—such as aspirin, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or anticoagulants like Warfarin—may increase the risk of bleeding. Close clinical monitoring is required for this combination. Setra is also an inhibitor of the CYP2D6 enzyme. When co-administered with other drugs primarily metabolized by CYP2D6, the dosage of the co-administered drug may require reduction.

Mechanism of Action

Setra, chemically sertraline, functions primarily as a selective serotonin reuptake inhibitor (SSRI) within the central nervous system. Its principal biological target is the serotonin transporter (SERT) protein, which is primarily located on the presynaptic membrane of serotonergic neurons .

Setra interacts with SERT as an inhibitor, binding to the transporter and allosterically modulating its function. This action impedes the reuptake of the neurotransmitter 5-hydroxytryptamine (5-HT) from the synaptic cleft back into the presynaptic neuron. The resultant consequence is an acute increase in the concentration of 5-HT within the synaptic space. Chronically, this sustained increase in synaptic 5-HT leads to neurochemical adaptation, specifically the desensitization and downregulation of somatodendritic 5-HT1A autoreceptors in the midbrain raphe. This desensitization subsequently permits a further increase in the firing rate of serotonergic neurons and sustained elevation of extracellular 5-HT in projection areas. The system-level physiological modulation involves altered serotonergic neurotransmission across various integrated brain pathways.

Dosage and Administration Information

Instruction Map: How to use Setra — administration guidelines

This section outlines the procedural requirements for the administration of Setra (Sertraline oral concentrate).

Administration scope

Route of administration: Oral. Dosing schedule: The dose is typically administered once daily, either in the morning or evening. The dosage range varies, with maximum daily adult doses generally not exceeding 200 mg for most uses. Dose adjustments, if needed, should not occur at intervals of less than one week. Timing in relation to meals (if applicable): May be taken with or without food. Preparation requirements (if applicable): The oral concentrate solution must be diluted immediately prior to administration. The required amount should be measured using the provided calibrated dropper and mixed with 4 ounces (1/2 cup) of a specific diluent: water, ginger ale, lemon/lime soda, lemonade, or orange juice only. The diluted mixture may appear hazy, which is normal. Do not mix with any other liquids. Age-group administration rules: Use in children aged 6 to 12 years is restricted to obsessive-compulsive disorder (OCD), commencing at a lower starting dose (25 mg daily) than for adults. For adolescents (13 to 17 years) with OCD, the starting dose is 50 mg daily. Missed-dose rules: If a dose is missed, take the next dose at the usual scheduled time. Do not double the dose to make up for the missed one.


Instruction classifications (high-level)

Administration method type: Oral. Frequency pattern: Daily (once a day) or Intermittent (e.g., for certain uses, daily dosing only during the luteal phase of the menstrual cycle).


Resulting procedural structure

Step sequence:

  • Measure the prescribed dose of oral concentrate using the calibrated dropper.
  • Dilute the concentrate by mixing it immediately with 4 ounces of an approved liquid (water, ginger ale, lemon/lime soda, lemonade, or orange juice).
  • Drink the entire diluted solution immediately.
  • Repeat once daily, at the same time, according to the prescribed schedule.

Connection to the overall use protocol: The administration protocol emphasizes the mandatory once-daily oral route and the requirement for dilution of the concentrate immediately before ingestion to prevent astringent effects. Dosage is specific to the patient's age and clinical use, with defined maximums. Adherence to the scheduled timing and the proper dilution procedure is integral to the overall use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Setra


Evidence for Use in Major Depressive Disorder (MDD) and OCD

The research base for how Setra has been studied in Major Depressive Disorder (MDD) is primarily built upon Randomized Controlled Trials (RCTs) and meta-analyses. These studies were used in research exploring how symptoms change over time, specifically for adult and older adult outpatients with MDD. The outcomes monitored included how depression severity scores evolved during the study period, and the time elapsed before the return of symptoms (recurrence) in longer continuation trials.

For Obsessive-Compulsive Disorder (OCD), research has explored the use of Setra in both adult and pediatric populations (children and adolescents) using Double-blind, Placebo-Controlled Trials (DBPCTs). Studies were applied in research contexts involving fluctuating or unstable symptoms, with outcomes related to the severity of obsessive thoughts and compulsive acts. The findings describe patterns observed in these studies, focusing on how symptom measures evolved across follow-up periods that extended up to 80 weeks.


Evidence for Anxiety and Stress-Related Conditions

Setra was studied for its use in several anxiety-related conditions, including Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder (SAD). For PD, studies were applied in research contexts involving episodic or acute changes, focusing on outcomes describing episodic or acute changes, such as the frequency of panic attacks. For PTSD, research examined both civilian and veteran populations using DBPCTs, evaluating changes across core symptom clusters.

For SAD, studies were relevant in trials assessing short-term symptom patterns, generally over 12 to 20 weeks. Research explored short-term symptom changes and described patterns related to changes in social phobia symptom scores. However, evidence is limited regarding how symptoms evolve over long-term outcomes.


What Remains Uncertain About the Research

Research contributes to the broader evidence landscape, but it also highlights what is still uncertain. The limitations across the body of research include that sample sizes were modest in some subgroup findings, and the resulting certainty in those specific analyses remains low. Evidence quality varies across studies, and findings were mixed when comparing certain populations. Comparative evidence involving Setra and other treatments is limited in some contexts, and data for those with severe co-occurring medical or psychiatric conditions remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Setra (FAQ)

Q: How quickly should I expect Setra to start working?

Studies and official information indicate that Setra's active ingredient takes about one week of once-daily dosing to reach a stable level in the body. While the drug starts working right away, the onset of noticeable clinical improvement varies among individuals. The clinical effect and timeline should be discussed with a healthcare provider.


Q: Can Setra be taken with over-the-counter pain relievers like ibuprofen?

Caution is advised when combining Setra with pain relievers that affect hemostasis, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen. According to regulatory documents, this combination may increase the risk of bleeding. A healthcare provider should be consulted before combining these medications.


Q: Is it normal to feel tired or dizzy when starting Setra?

Yes, Dizziness and Somnolence (Drowsiness) are listed as Common adverse reactions in the official product information. This means they occurred in 1% to less than 10% of patients in clinical trials. Any severe or concerning side effects should be reviewed by a healthcare professional.


Q: Are there any foods or drinks to avoid while taking Setra?

If you are using the oral concentrate solution, the product information states that it must be mixed with only approved liquids like water, ginger ale, or orange juice. The oral concentrate solution requires dilution with only approved liquids before ingestion. For the tablets, regulatory documents do not list specific food restrictions, though absorption may be slightly affected by food.


Q: How do I know if Setra is working for me?

During clinical trials, effectiveness was tracked by monitoring changes in symptom severity scores (e.g., depression or anxiety scales). Therapeutic response is assessed by a physician throughout treatment, often using clinical measures related to symptom severity. The determination of effectiveness should always be made by a healthcare provider.


Q: Does Setra cause stomach upset or digestive issues?

Yes, Nausea and Diarrhea or Loose Stool are among the most frequently reported side effects. Official product information classifies these as Very Common adverse reactions, meaning they occurred in 10% of patients in clinical trials. This is a known effect on the gastrointestinal system.


Q: Is it better to take Setra in the morning or at night?

Regulatory documents state that Setra is administered once daily, and it may be taken either in the morning or evening. The choice between morning and evening administration is flexible and is typically determined in consultation with a healthcare provider.


Q: How long does Setra stay in your system after stopping?

The half-life (the time it takes for half the drug to be eliminated) of Setra is about 26 hours. However, its major metabolite, which is also active, has a longer half-life, ranging from 62 to 104 hours. Due to the longer half-life of the active metabolite, complete clearance from the body takes several days.


Q: Is Setra safe for older adults or seniors?

Official information notes that there are generally no geriatric-related problems that limit the drug's use in older adults. However, this population may be at a greater risk for developing Hyponatremia (low sodium levels), and dose adjustments may be needed due to reduced drug clearance.


Q: What kind of monitoring is needed while taking Setra?

Close monitoring by a physician is required, particularly when starting the drug or changing the dose. Regulatory warnings emphasize monitoring for signs of suicidal thoughts/behaviors, the emergence of Serotonin Syndrome, activation of mania/hypomania, and abnormal bleeding.


Q: Does Setra have an impact on mood?

Setra is indicated for and works to modulate conditions that involve mood-related distress, such as Major Depressive Disorder. However, official warnings also note the potential for Activation of Mania or Hypomania in certain susceptible individuals, requiring careful monitoring.


Q: Is there a generic version of Setra available?

Yes, the active ingredient in Setra, sertraline hydrochloride, is a widely available compound. It is approved and distributed by regulators in generic tablet and oral solution forms.


Q: Are there specific patient groups that respond better to Setra?

Clinical trials showed effectiveness in the studied populations, which included adults and pediatric patients with OCD. Regulatory documents do not specifically single out one demographic as guaranteed to respond better, though individual results will vary.


Q: Is there evidence that Setra works differently for men vs. women?

Official regulatory data suggests that the way the body processes the drug (pharmacokinetics) is generally not different between sexes. However, adverse reaction tables do list specific sexual side effects, such as ejaculation failure and female anorgasmia, separately for men and women.


Q: Are there documented cases of Setra withdrawal symptoms?

Yes, regulatory documents mention a risk of Discontinuation Syndrome. This means that adverse reactions may occur when Setra is stopped. Common symptoms can include dizziness, nausea, headache, and sensory disturbances, and discontinuation should be managed by a healthcare provider.


Q: Is Setra considered a controlled substance?

No, Setra (sertraline) is not classified as a controlled substance by major regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA).


Q: Is Setra effective for chronic conditions?

Regulatory trials include long-term continuation studies for conditions like Major Depressive Disorder and OCD to assess the maintenance of effect over time. The need for extended or chronic use is subject to periodic reevaluation by a physician, as stated in regulatory guidelines.

How should Setra be stored and disposed of?

How to Store and Dispose of Setra (Sertraline)


The storage and disposal of Setra (Sertraline) must follow mandatory regulatory requirements to ensure product quality and environmental safety.

Storage Conditions

The medicine, including tablets, must be stored at a controlled room temperature between 20°C and 25°C. It is required to keep the container closed tightly and protect the medicine from freezing, excessive heat, and moisture. All forms of Setra must be stored out of the reach of children.

Disposal Instructions

If using the oral concentrate solution, discard the bottle 30 days after first opening. Unused or expired medication should be disposed of according to local and national regulations, such as through a designated take-back program. Disposal into wastewater or the environment is restricted due to the active ingredient's classification as toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Setra found in:

A-Z Index: